MediLexicon News - OssulinTM, A Novel Oral Insulin Product, Shows Promising Bioavailability For Advancing Diabetes Therapy

news headlines

email to a friend

printer friendly

OssulinTM, A Novel Oral Insulin Product, Shows Promising Bioavailability For Advancing Diabetes Therapy

Main Category: Diabetes

Article Date: 10 Nov 2009

New data from Puredel Limited, presented at the 9th Annual Diabetes Technology Meeting in San Francisco, CA, suggests that higher blood levels of insulin were achieved by Ossulin™ than had been previously demonstrated by other oral products. In a series of experiments covering a range of doses and models, Ossulin™ consistently delivered around 20% of the insulin dose into the bloodstream.

The authors concluded that:

"Ossulin provides an efficient way to deliver insulin to the body via oral administration, resulting in blood levels higher than those previously observed with other oral insulin products."

Lead author and Chief Scientific Officer for Puredel, Dr. Marco Prosdocimi added:

"Oral insulin could represent a major advance in diabetes therapy through its simplicity of use, and because it mimics the natural physiological route of the hormone. The incorporation of insulin into the proprietary delivery agent NatsomTM gives rise to a product which is not destroyed by the gastric environment."

Source
Puredel Limited

Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today

Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles.

< back to medical news

For any corrections of factual information, or to contact the editors please use our feedback form.

Send your press releases to

OssulinTM, A Novel Oral Insulin Product, Shows Promising Bioavailability For Advancing Diabetes Therapy

Medical Terminology Forums